SEC Filing Summary: Merck & Co., Inc. (13F-HR)
Business Context and Reporting Period
This filing is a Form 13F-HR submitted by Merck & Co., Inc. as an Institutional Investment Manager. The report covers the quarter ended June 30, 2026. The filing was signed by Kelly Grez, Corporate Secretary, on August 7, 2026. It includes holdings for one other included manager: Merck Sharp & Dohme LLC.
Key Financial Metrics
As a Form 13F, this document reports equity holdings rather than the company's operational financial performance. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity for Merck & Co., Inc. are not present in this filing.
- Total Value of Reported Holdings: $526,407,169
- Number of Holdings Reported: 13
- Number of Other Included Managers: 1
Material Changes
The filing text does not provide comparative data against the prior period (March 31, 2026) to determine material changes in holdings or values. The document lists only the current quarter's aggregate totals.
Guidance, Outlook, and Risks
This filing type does not contain management commentary, forward-looking guidance, risk factors, or contingencies regarding the company's business operations. It strictly discloses the portfolio of securities held by the reporting manager.
Investor Verification Checklist
- Verify the specific 13 equity positions held by Merck & Co., Inc. in the full schedule (not included in this summary text).
- Confirm the total portfolio value of $526,407,169 against the prior quarter's 13F filing to assess net buying or selling activity.
- Note that this report reflects Merck's role as an investment manager, not its own pharmaceutical or healthcare business results.